Relay Therapeutics (RLAY) to Release Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is projected to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Relay Therapeutics to post earnings of ($0.38) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Relay Therapeutics Stock Up 2.6%

Shares of NASDAQ RLAY opened at $9.16 on Wednesday. The company has a market cap of $1.59 billion, a P/E ratio of -5.23 and a beta of 1.59. Relay Therapeutics has a 52 week low of $1.77 and a 52 week high of $9.54. The business has a 50-day simple moving average of $8.20 and a two-hundred day simple moving average of $6.44.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, insider Peter Rahmer sold 11,684 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the completion of the sale, the insider directly owned 277,964 shares in the company, valued at $2,118,085.68. This represents a 4.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $143,979.90. Following the completion of the transaction, the insider owned 422,733 shares in the company, valued at approximately $3,221,225.46. This represents a 4.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,302 shares of company stock worth $724,355 in the last quarter. 4.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Relay Therapeutics

Several hedge funds have recently made changes to their positions in the business. Commodore Capital LP purchased a new stake in Relay Therapeutics in the second quarter worth approximately $46,191,000. Bellevue Group AG grew its stake in shares of Relay Therapeutics by 1.4% during the 3rd quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after purchasing an additional 114,740 shares during the period. State Street Corp grew its stake in shares of Relay Therapeutics by 26.8% during the 4th quarter. State Street Corp now owns 6,426,111 shares of the company’s stock valued at $54,365,000 after purchasing an additional 1,360,121 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Relay Therapeutics by 11.6% in the fourth quarter. Geode Capital Management LLC now owns 3,409,363 shares of the company’s stock worth $28,849,000 after buying an additional 354,777 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after buying an additional 374,491 shares during the last quarter. 96.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RLAY has been the subject of a number of analyst reports. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $13.00 in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target for the company in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.